Skip to main content
. 2017 Mar;33(2):139–149. doi: 10.6515/ACS20160427B

Figure 1.

Figure 1

The 124 chronic heart failure patients were divided into two groups, depending upon whether or not their circulating adiponectin levels were above or below the median at 3-month follow-up. Those patients with adiponectin levels above the median had a significant worse outcomes compared to those adiponectin levels were below the median (log-rank p = 0.005).